Page last updated: 2024-08-26

bosentan anhydrous and Heart Diseases

bosentan anhydrous has been researched along with Heart Diseases in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM1
Coons, JC; Kido, K1
Díaz-Caraballo, E; García-Río, F; González-García, AE; Oliver-Ruiz, JM; Reñones, M; Sánchez-Recalde, A1
Borst, MM; Enke, B; Ewert, R; Gilbert, N; Gruenig, E; Hoeper, MM; Lange, PE; Schulze-Neick, I; Witt, C1
Kapoor, S1

Reviews

1 review(s) available for bosentan anhydrous and Heart Diseases

ArticleYear
Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
    Pharmacotherapy, 2019, Volume: 39, Issue:9

    Topics: Bosentan; Endothelin Receptor Antagonists; Heart Diseases; Hemodynamics; Humans; Pulmonary Arterial Hypertension; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides

2019

Trials

1 trial(s) available for bosentan anhydrous and Heart Diseases

ArticleYear
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
    American heart journal, 2005, Volume: 150, Issue:4

    Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Female; Heart Diseases; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides

2005

Other Studies

3 other study(ies) available for bosentan anhydrous and Heart Diseases

ArticleYear
Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity.
    Toxicology, 2022, 01-15, Volume: 465

    Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Bosentan; Cardiotoxicity; Endothelin Receptor Antagonists; Fluorouracil; Heart Diseases; Myeloid Differentiation Factor 88; Myocytes, Cardiac; NF-kappa B; Nitric Oxide Synthase Type III; Oxidative Stress; Rats, Wistar; Receptors, Endothelin; Signal Transduction; Toll-Like Receptor 4

2022
Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome.
    Revista espanola de cardiologia, 2009, Volume: 62, Issue:9

    Topics: Adult; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Heart Diseases; Humans; Male; Sulfonamides; Time Factors

2009
Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases.
    Rheumatology international, 2008, Volume: 29, Issue:1

    Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Heart Diseases; Humans; Hypertension, Pulmonary; Respiratory Function Tests; Sulfonamides; Thoracic Diseases

2008